Readoutin 14d
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair — Raloxifene - Usual
Phase 3 primary completion: Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms.
- Date
- Dec 2026
- Type
- Readout
- Indication
- Breast Cancer